Industry Strength Score
10/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ABBOTT LABORATORIES (ABL.DE) Stock Price & Overview
FRA:ABL • US0028241000
Current stock price
79.1 EUR
-0.94 (-1.17%)
Last:
The current stock price of ABL.DE is 79.1 EUR. Today ABL.DE is down by -1.17%. In the past month the price decreased by -11.77%. In the past year, price decreased by -31.71%.
ABL.DE Key Statistics
52-Week Range77.5 - 120.54
Current ABL.DE stock price positioned within its 52-week range.
1-Month Range77.5 - 90.64
Current ABL.DE stock price positioned within its 1-month range.
- Market Cap
- 137.45B
- P/E
- 17.74
- Fwd P/E
- 14.70
- EPS (TTM)
- 4.46
- Dividend Yield
- 2.72%
ABL.DE Stock Performance
Today
-1.17%
1 Week
+0.41%
1 Month
-11.77%
3 Months
-12.36%
Longer-term
6 Months -26.27%
1 Year -31.71%
2 Years -19.79%
3 Years -20.51%
5 Years -20.59%
10 Years +129.45%
ABL.DE Stock Chart
ABL.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ABL.DE. When comparing the yearly performance of all stocks, ABL.DE is a bad performer in the overall market: 92.21% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ABL.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to ABL.DE. Both the health and profitability get an excellent rating, making ABL.DE a very profitable company, without any liquidiy or solvency issues.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ABL.DE Earnings
On April 16, 2026 ABL.DE reported an EPS of 1.15 and a revenue of 11.16B. The company missed EPS expectations (-0.45% surprise) and beat revenue expectations (0.5% surprise).
Next Earnings DateJul 15, 2026
Last Earnings DateApr 16, 2026
PeriodQ1 / 2026
EPS Reported$1.15
Revenue Reported11.164B
EPS Surprise -0.45%
Revenue Surprise 0.50%
ABL.DE Forecast & Estimates
35 analysts have analysed ABL.DE and the average price target is 113.78 EUR. This implies a price increase of 43.85% is expected in the next year compared to the current price of 79.1.
For the next year, analysts expect an EPS growth of 10.72% and a revenue growth 8.79% for ABL.DE
Analysts
Analysts80.57
Price Target113.78 (43.84%)
EPS Next Y10.72%
Revenue Next Year8.79%
ABL.DE Financial Highlights
Over the last trailing twelve months ABL.DE reported a non-GAAP Earnings per Share(EPS) of 4.46. The EPS increased by 9% compared to the year before.
Income Statements
Revenue(TTM)45.13B
Net Income(TTM)6.52B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.72% | ||
| ROA | 7.52% | ||
| ROE | 12.51% | ||
| Debt/Equity | 0.19 |
Chartmill High Growth Momentum
EPS Q2Q%5.5%
Sales Q2Q%7.78%
EPS 1Y (TTM)9%
Revenue 1Y (TTM)6.59%
ABL.DE Ownership
Ownership
Inst Owners81.92%
Shares1.74B
Float1.73B
Ins Owners0.47%
Short Float %N/A
Short RatioN/A
ABL.DE Industry Overview
ABL.DE operates in the Health Care Equipment sub-industry within the Health Care sector. This group contains 127 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
61/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
13%
Outperformed 13% of sub-industries
3 Month Rank
10%
Outperformed 10% of sub-industries
6 Month Rank
10%
Outperformed 10% of sub-industries
Industry Fundamentals & Breadth
- Members
- 127
- New Highs
- 2.4%
- New Lows
- 13.4%
- Average ROE
- 17.2%
- Average Profit Margin
- 20.4%
- Average Operating Margin
- 22.4%
- Average P/E
- 28.0
- Average Fwd P/E
- 23.9
- Average Debt/Equity
- 0.5
ABL.DE Competitors/Peers
The largest stocks on the EU markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 2M6 | MEDTRONIC PLC | 12.98 | 90.334B | ||
| SHL | SIEMENS HEALTHINEERS AG | 12.82 | 39.773B | ||
| PHIA | KONINKLIJKE PHILIPS NV | 14.46 | 22.292B | ||
| PHI1 | KONINKLIJKE PHILIPS NV | 14.45 | 22.292B | ||
| BIM | BIOMERIEUX | 14.16 | 8.262B | ||
| OBCK | OTTOBOCK SE & CO KGAA | 19.17 | 3.622B | ||
| DIA | DIASORIN SPA | 14.07 | 3.242B | ||
| AFX | CARL ZEISS MEDITEC AG - BR | 13.51 | 2.302B | ||
| DRW3 | DRAEGERWERK AG - PREF | 10.99 | 1.722B | ||
| DRW8 | DRAEGERWERK AG | 8.52 | 1.366B | ||
| ELN | EL.EN. SPA | 17.28 | 1.047B | ||
| EUZ | ECKERT & ZIEGLER SE | 18.56 | 959.152M | ||
| GVS | GVS SPA | 15.96 | 792.664M |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About ABL.DE
Company Profile
Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. The company is headquartered in Abbott Park, Illinois and currently employs 115,000 full-time employees. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. The company serves people in more than 160 countries.
Company Info
IPO: 1937-03-01
ABBOTT LABORATORIES
100 Abbott Park Road, Abbot Park
ABBOTT PARK ILLINOIS US
Employees: 115000
Phone: 12246676100
ABBOTT LABORATORIES / ABL.DE FAQ
What does ABL do?
Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. The company is headquartered in Abbott Park, Illinois and currently employs 115,000 full-time employees. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. The company serves people in more than 160 countries.
Can you provide the latest stock price for ABBOTT LABORATORIES?
The current stock price of ABL.DE is 79.1 EUR. The price decreased by -1.17% in the last trading session.
Does ABBOTT LABORATORIES pay dividends?
ABBOTT LABORATORIES (ABL.DE) has a dividend yield of 2.72%. The yearly dividend amount is currently 2.03.
How is the ChartMill rating for ABBOTT LABORATORIES?
ABL.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for ABL.DE stock?
35 analysts have analysed ABL.DE and the average price target is 113.78 EUR. This implies a price increase of 43.85% is expected in the next year compared to the current price of 79.1.
What is the market capitalization of ABL stock?
ABBOTT LABORATORIES (ABL.DE) has a market capitalization of 137.45B EUR. This makes ABL.DE a Large Cap stock.
When does ABBOTT LABORATORIES (ABL.DE) report earnings?
ABBOTT LABORATORIES (ABL.DE) will report earnings on 2026-07-15, before the market open.